QDEL Stock — QuidelOrtho Corp

Up next

Next earnings call

Feb 10, 2027 Est · unconfirmed · in 12 wks

Q3 2026 earnings call transcript

call held Nov 3, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 4

Quarterly report 10-Q FY2026 Q3, ended Sep 27

Revenue Falls as Restructuring Targets 2027 Savings

QuidelOrtho Corporation reported nine-month revenue of $1,869.6 million, down 7%, amid respiratory-product declines, a terminated Joint Business arrangement and China pricing pressure. It also launched a restructuring program targeting over $80 million in annual savings in 2027.

Revenue $618.9M ▼ 11.6% Net loss $53.8M Diluted EPS -$0.78

Read from the MD&A section

4 source passages

For the nine months ended September 27, 2026, Total revenues decreased by 7% to $1,869.6 million as compared to the same period in the prior year. This decrease was primarily driven by (i) variability of our U.S. respiratory products, mainly due to decreases in flu and COVID-19 revenues, (ii) the termination of our Joint Business arrangement and (iii) evolving market dynamics in China. In the fourth quarter of 2026, we launched a new cost transformation and enterprise restructuring program designed to further improve our cost structure and evolve our operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics. We expect the program to deliver over $80 million in annual savings in 2027 and to record approximately $30 to $35 million in one-time restructuring charges in the fourth quarter of 2026. Open the document at this passage

Nov 3

Earnings call

Restructuring targets over $80 million savings in 2027

Quidel Ortho reported third-quarter revenue of $619 million, down 12%, as China revenue declined 45%. It launched a restructuring program targeting over $80 million in annual savings in 2027 and narrowed 2026 revenue guidance to $2.52 to $2.54 billion.

5 source passages

Welcome to the Quidel Ortho 3rd Quarter 2026 Financial Results Conference Call and Webcast. Total reported revenue was $619 million, down 12% from last year. China revenue declined 45% year-over-year as distributors and customers continued to reduce purchasing and inventory levels related to the nationwide IBD pricing guidelines, which were finalized in mid-August. We expect this program to deliver over $80 million in annual savings in 2027. Based on our current outlook, we are narrowing full-year revenue guidance from $2.52 to $2.6 billion, To a range of $2.52 to $2.54 billion. Open the document at this passage

Nov 3

Current report 8-K

Restructuring targets over $80 million annual savings in 2027

QuidelOrtho expects its restructuring program to deliver over $80 million in annual savings in 2027, with approximately $30 to $35 million in fourth-quarter 2026 charges; third-quarter revenue was $619 million and adjusted EBITDA was $148 million.

Financial results, Director or officer change, or executive pay

3 source passages

The Company expects the program to deliver over $80 million in annual savings in 2027 and to record approximately $30 to $35 million in one-time restructuring charges in the fourth quarter of 2026. Total revenue was $619 million, a decrease of 12% both as reported and in constant currency. GAAP net loss was $54 million; GAAP operating loss was $8 million; adjusted EBITDA was $148 million. Open the document at this passage

Sep 23

Current report 8-K

Entered into a material agreement

QuidelOrtho amended its credit agreement to reset financial covenants through the quarter ending September 30, 2029, allowing 5.50 to 1.00 leverage, with initial Term Loan A and revolving rates of 1.50% for base loans and 2.50% for Term SOFR loans.

Read from the first part of this long document

Aug 7

Quarterly report 10-Q FY2026 Q2, ended Jun 28

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $630.9M ▲ 2.8% Net loss $92.9M Diluted EPS -$1.36

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$2.59B

Trailing 12 months

Net income (TTM)

−$369.20M

Trailing 12 months

Revenue growth YoY

-11.6%

Year over year

Operating margin

-4.9%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-15.9%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$2.77B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1.0%

Year over year · more shares

Price change (1Y)

-51.6%

Trailing year

Short interest

21.1%

Latest settlement · 7.6 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▼4.7% $707.80M −$178.40M '24 Q4* ▼2.6% $692.80M −$12.70M '25 Q1 ▼3.6% $613.90M −$255.40M '25 Q2 ▼3.7% $699.90M −$733.00M '25 Q3 ▲2.2% $723.60M −$130.70M '25 Q4* ▼10.5% $619.80M −$91.80M '26 Q1 ▲2.8% $630.90M −$92.90M '26 Q2 LATEST ▼11.6% $618.90M −$53.80M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Nov 3, 2026

Q3 FY26

TL;DR. Revenue excluding respiratory, China and the donor-screening wind-down grew 3%, free cash flow improved to $0.3 million, and the restructuring program targets over $80 million of annual savings in 2027. However, reported revenue fell 12%, guidance ranges were narrowed, margins and adjusted EBITDA weakened, China’s revenue mix is expected to decline, and net leverage increased.

Bullish

+ Revenue excluding respiratory, China and the U.S. Donor Screening wind-down grew 3% in constant currency.
+ Free cash flow improved to $0.3 million from negative $94.7 million in the prior-year quarter.
+ Non-GAAP operating expenses declined 3% to approximately $210 million.
+ The cost transformation and restructuring program is expected to deliver over $80 million of annual savings in 2027.
+ The amended credit agreement provides additional covenant capacity through the second quarter of 2028.

Bearish

− The restructuring program will produce approximately $30 million to $35 million of one-time fourth-quarter charges, with a majority of the cash outflow occurring in the quarter.
− Net leverage increased to 4.5 times adjusted EBITDA from 4.3 times, primarily because of the revenue-driven decline in trailing 12-month adjusted EBITDA.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −30%

below

Price vs 50-day avg −13%

below

RSI (14) 39

neutral

MACD trend Negative

52-week position 3%

near low

Momentum

relative strength

Very Weak

1-month return −17%

trailing

6-month return −10%

trailing

YTD return −62%

this year

Relative strength −11%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $12 › 200d $15 — 200d above 50d

Institutional flow Distributing

220 of 249 funds reported for Sep 30 · net -3.0M sh shares · +28 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

21.08% of shares out · ▲ +11.3% MoM · 7.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

249 holders — near 3-yr low, contrarian setup

Squeeze score 73

high risk · 0–100

Fundamentals

Weak

Revenue growth −2%

Y/Y

EPS growth +45%

Y/Y

Free cash flow $-83.0M

Buyback $218.4M

remaining

Balance sheet $2.5B

net debt

Quant / Vol

risk profile

Very High

Volatility 91%

annualized · 1-yr

Max drawdown −72%

past year

ATR 11.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 4 of last 4

Latest guidance · from the 8-K filed Aug 6, 2026

Total revenues (reported) · Full-year 2026 Lowered $2.52B – $2.6B

May 5, 2026 $2.7B – $2.75B Aug 6, 2026 $2.52B – $2.6B

prior FY $2.73B midpoint −6.2% Y/Y

Adjusted EBITDA · Full-year 2026 Lowered $540M – $560M

May 5, 2026 $615M – $630M Aug 6, 2026 $540M – $560M

Adjusted diluted EPS · Full-year 2026 Lowered $0.65 – $0.90

May 5, 2026 $1.80 – $2.00 Aug 6, 2026 $0.65 – $0.90

Adjusted EBITDA margin · Full-year 2026 Lowered 21% – 22%

May 5, 2026 23% Aug 6, 2026 21% – 22%

Previous outlook earlier release · from the 8-K filed May 5, 2026

Still-open targets the latest release did not restate under the same label.

Free cash flow · Full-year 2026 $100M – $120M

Prior guidance period ended · from the 8-K filed Apr 15, 2026

Preliminary unaudited revenue, as reported · first quarter of 2026 $615M – $620M

Free cash flow · first quarter of 2026 $-70M – $-65M

Guided vs delivered · last 4 settled

Total revenues (reported) Full-year 2025

guided $2.68B – $2.74B

guided $2.68B – $2.74B $2.73B In line

Total revenues (reported) fiscal year 2024

guided $2.76B – $3.07B

guided $2.76B – $3.07B $2.78B In line

Total revenues (reported) Fiscal Year 2023

guided $2.88B – $3.08B

guided $2.88B – $3.08B $3B In line

COVID-related revenue fiscal year 2022

guided $1.29B – $1.34B

guided $1.29B – $1.34B $3.27B Beat +148.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 2 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−30% Bearish

Price vs 50-day avg

−13% Bearish

RSI (14)

39 Neutral

MACD trend

Negative Bearish

52-week position

3% Bearish

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $12 › 200d $15 — 200d above 50d

Institutional flow Distributing

220 of 249 funds reported for Sep 30 · net -3.0M sh shares · +28 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

21.08% of shares out · ▲ +11.3% MoM · 7.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

249 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

Range low $10 Now $11 · 3% Range high $35

vs 200-day avg -30% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted diluted EPS non-GAAP	$0.13	Q2 FY2026	—
Adjusted EBITDA non-GAAP	$238M	Six Months Ended June 28, 2026	—
Adjusted EBITDA margin non-GAAP	20.5%	Q2 FY2026	—
Adjusted net income non-GAAP	$6.8M	Six Months Ended June 28, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
QDEL QuidelOrtho Corp this stock	$736.90M	-62.4%	-1.9%	—	21.1%
ABT Abbott Laboratories	$187.95B	-13.4%	+5.7%	40.5	1.1%
MDT Medtronic plc	$131.57B	+7.1%	+8.4%	25.3	1.8%
SYK Stryker Corp	$117.88B	-11.9%	+11.2%	33.0	1.7%
BSX Boston Scientific Corp	$64.27B	-53.5%	+12.5%	18.8	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

238

% held: 117.6%
Reported: 220 of 249
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

249

View

Short & Settlement

Short Interest Rising

Shares short

14.5M

Days to cover: 7.6d
Change: +1.5M sh

View

Short Volume

Short vol %

24%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

1.2K

Value: $14.6K
As of: Oct 8, 2026

View

Off-Exchange

Off-exchange %

50.3%

Week of: Oct 5, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Jul 12, 2023

View

Financials

Revenue (FY)

$2.7B

Net income (FY): $-1.1B
EPS diluted: $-16.69

View

Buybacks

Authorized

$300.0M

Remaining: $218.4M

Spent Remaining

View

Filings

SEC Filings

Latest

10-Q

Filed: Nov 4, 2026
This year: 21

QuidelOrtho Corporation reported nine-month revenue of $1,869.6 million, down 7%, amid respiratory-product declines, a terminated Joint Business arrangement and China pricing pressure. It also launched a restructuring program targeting over $80 million in annual savings in 2027.

View

Proposed Sales

Value

$112.0K

Shares: 4.0K
Filed: Nov 25, 2025

View

Earnings & Events

Webcasts

Last webcast

Nov 3, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
QDEL	+0.4%	-16.8%	-10.4%	-18.9%	-62.4%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	-2.2%	-15.7%	-10.9%	-18.8%	-73.0%

QDEL · QuidelOrtho Corp

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns